Meeder Asset Management Inc. Grows Stock Holdings in Catalent Inc (NYSE:CTLT)
Meeder Asset Management Inc. increased its stake in shares of Catalent Inc (NYSE:CTLT) by 7.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,997 shares of the company’s stock after purchasing an additional 1,747 shares during the period. Meeder Asset Management Inc.’s holdings in Catalent were worth $1,355,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC bought a new stake in Catalent during the second quarter valued at approximately $32,000. Advisory Services Network LLC grew its position in Catalent by 115.5% during the second quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares during the period. Bremer Bank National Association bought a new stake in Catalent during the first quarter valued at approximately $49,000. Financial Gravity Wealth Inc. bought a new stake in Catalent during the first quarter valued at approximately $47,000. Finally, Zions Bancorporation N.A. bought a new stake in Catalent during the first quarter valued at approximately $61,000. 99.94% of the stock is owned by hedge funds and other institutional investors.
Shares of CTLT traded down $0.03 during mid-day trading on Wednesday, reaching $55.74. The stock had a trading volume of 58,172 shares, compared to its average volume of 644,031. The firm has a market cap of $8.14 billion, a price-to-earnings ratio of 35.06, a PEG ratio of 2.74 and a beta of 1.64. Catalent Inc has a 12 month low of $29.23 and a 12 month high of $58.38. The business has a fifty day moving average of $55.44 and a 200 day moving average of $47.05. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.71 and a current ratio of 2.18.
Several analysts recently issued reports on CTLT shares. Jefferies Financial Group upgraded shares of Catalent from a “hold” rating to a “buy” rating and boosted their target price for the company from $50.00 to $62.00 in a research report on Friday, June 21st. Zacks Investment Research lowered shares of Catalent from a “hold” rating to a “sell” rating in a research report on Monday. Finally, UBS Group boosted their target price on shares of Catalent to $64.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $55.14.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Holder of Record
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.